Skip to main content

Hepatitis clinical trials at UC Davis

1 research study open to eligible people

Showing trials for
  • Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

    open to eligible people ages 18 years and up

    The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater than or equal to (>=) 32 and Model for End-stage Liver Disease (MELD) scores 21-30, inclusive.

    Sacramento, California and other locations

Last updated: